- Home
- SEDG vs PHVS Comparison
SEDG vs PHVS Comparison
Compare SEDG & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEDG
- PHVS
- Stock Information
- Founded
- SEDG 2006
- PHVS 2015
- Country
- SEDG Israel
- PHVS Netherlands
- Employees
- SEDG N/A
- PHVS N/A
- Industry
- SEDG Semiconductors
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- SEDG Technology
- PHVS Health Care
- Exchange
- SEDG Nasdaq
- PHVS Nasdaq
- Market Cap
- SEDG 770.2M
- PHVS 894.8M
- IPO Year
- SEDG 2015
- PHVS 2021
- Fundamental
- Price
- SEDG $17.62
- PHVS $16.49
- Analyst Decision
- SEDG Hold
- PHVS Strong Buy
- Analyst Count
- SEDG 27
- PHVS 5
- Target Price
- SEDG $26.45
- PHVS $41.60
- AVG Volume (30 Days)
- SEDG 5.1M
- PHVS 35.8K
- Earning Date
- SEDG 02-19-2025
- PHVS 04-09-2025
- Dividend Yield
- SEDG N/A
- PHVS N/A
- EPS Growth
- SEDG N/A
- PHVS N/A
- EPS
- SEDG N/A
- PHVS N/A
- Revenue
- SEDG $901,456,000.00
- PHVS N/A
- Revenue This Year
- SEDG $25.57
- PHVS N/A
- Revenue Next Year
- SEDG $35.25
- PHVS N/A
- P/E Ratio
- SEDG N/A
- PHVS N/A
- Revenue Growth
- SEDG N/A
- PHVS N/A
- 52 Week Low
- SEDG $10.24
- PHVS $15.21
- 52 Week High
- SEDG $78.41
- PHVS $28.17
- Technical
- Relative Strength Index (RSI)
- SEDG 61.46
- PHVS 36.48
- Support Level
- SEDG $12.95
- PHVS $17.01
- Resistance Level
- SEDG $23.77
- PHVS $17.94
- Average True Range (ATR)
- SEDG 1.50
- PHVS 0.71
- MACD
- SEDG 0.51
- PHVS -0.09
- Stochastic Oscillator
- SEDG 46.24
- PHVS 17.44
About SEDG SolarEdge Technologies Inc.
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.